deCODE genetics, Amgen, Reykjavik, Iceland.
School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
JAMA Cardiol. 2024 Feb 1;9(2):165-172. doi: 10.1001/jamacardio.2023.4820.
Recurrent pericarditis is a treatment challenge and often a debilitating condition. Drugs inhibiting interleukin 1 cytokines are a promising new treatment option, but their use is based on scarce biological evidence and clinical trials of modest sizes, and the contributions of innate and adaptive immune processes to the pathophysiology are incompletely understood.
To use human genomics, transcriptomics, and proteomics to shed light on the pathogenesis of pericarditis.
DESIGN, SETTING, AND PARTICIPANTS: This was a meta-analysis of genome-wide association studies of pericarditis from 5 countries. Associations were examined between the pericarditis-associated variants and pericarditis subtypes (including recurrent pericarditis) and secondary phenotypes. To explore mechanisms, associations with messenger RNA expression (cis-eQTL), plasma protein levels (pQTL), and CpG methylation of DNA (ASM-QTL) were assessed. Data from Iceland (deCODE genetics, 1983-2020), Denmark (Copenhagen Hospital Biobank/Danish Blood Donor Study, 1977-2022), the UK (UK Biobank, 1953-2021), the US (Intermountain, 1996-2022), and Finland (FinnGen, 1970-2022) were included. Data were analyzed from September 2022 to August 2023.
Genotype.
Pericarditis.
In this genome-wide association study of 4894 individuals with pericarditis (mean [SD] age at diagnosis, 51.4 [17.9] years, 2734 [67.6%] male, excluding the FinnGen cohort), associations were identified with 2 independent common intergenic variants at the interleukin 1 locus on chromosome 2q14. The lead variant was rs12992780 (T) (effect allele frequency [EAF], 31%-40%; odds ratio [OR], 0.83; 95% CI, 0.79-0.87; P = 6.67 × 10-16), downstream of IL1B and the secondary variant rs7575402 (A or T) (EAF, 45%-55%; adjusted OR, 0.89; 95% CI, 0.85-0.93; adjusted P = 9.6 × 10-8). The lead variant rs12992780 had a smaller odds ratio for recurrent pericarditis (0.76) than the acute form (0.86) (P for heterogeneity = .03) and rs7575402 was associated with CpG methylation overlapping binding sites of 4 transcription factors known to regulate interleukin 1 production: PU.1 (encoded by SPI1), STAT1, STAT3, and CCAAT/enhancer-binding protein β (encoded by CEBPB).
This study found an association between pericarditis and 2 independent sequence variants at the interleukin 1 gene locus. This finding has the potential to contribute to development of more targeted and personalized therapy of pericarditis with interleukin 1-blocking drugs.
复发性心包炎是一种治疗挑战,通常也是一种使人虚弱的病症。白细胞介素 1 细胞因子抑制剂类药物是一种很有前途的新治疗选择,但它们的使用基于稀缺的生物学证据和规模适度的临床试验,而且先天和适应性免疫过程对病理生理学的贡献还不完全清楚。
利用人类基因组学、转录组学和蛋白质组学来阐明心包炎的发病机制。
设计、地点和参与者:这是一项来自 5 个国家的心包炎全基因组关联研究的荟萃分析。研究检查了心包炎相关变体与心包炎亚型(包括复发性心包炎)和次要表型之间的关联。为了探讨机制,评估了与信使 RNA 表达(顺式-eQTL)、血浆蛋白水平(pQTL)和 DNA 甲基化(ASM-QTL)的关联。纳入了来自冰岛(deCODE genetics,1983-2020 年)、丹麦(哥本哈根医院生物库/丹麦献血者研究,1977-2022 年)、英国(英国生物库,1953-2021 年)、美国(Intermountain,1996-2022 年)和芬兰(FinnGen,1970-2022 年)的数据。数据于 2022 年 9 月至 2023 年 8 月进行分析。
基因型。
心包炎。
在这项对 4894 名心包炎患者(诊断时的平均[SD]年龄为 51.4[17.9]岁,2734[67.6%]为男性,不包括 FinnGen 队列)的全基因组关联研究中,在 2 号染色体 2q14 上白细胞介素 1 基因座发现了 2 个独立的常见基因间变异与心包炎相关。主要变异是 rs12992780(T)(效应等位基因频率[EAF],31%-40%;比值比[OR],0.83;95%置信区间[CI],0.79-0.87;P = 6.67×10-16),位于 IL1B 下游,次要变异是 rs7575402(A 或 T)(EAF,45%-55%;调整 OR,0.89;95%CI,0.85-0.93;调整 P = 9.6×10-8)。主要变异 rs12992780 与复发性心包炎(OR,0.76)的比值比小于急性心包炎(OR,0.86)(异质性 P = .03),rs7575402 与 4 个已知调节白细胞介素 1 产生的转录因子的重叠结合位点的 CpG 甲基化相关:PU.1(由 SPI1 编码)、STAT1、STAT3 和 CCAAT/增强子结合蛋白 β(由 CEBPB 编码)。
本研究发现白细胞介素 1 基因座与心包炎之间存在关联。这一发现有可能促进白细胞介素 1 阻断药物更有针对性和个性化的心包炎治疗的发展。